Aggressive fibromatosis is a mesenchymal neoplasm associated with mutations, resulting in b-catenin-mediated transcriptional activation. We found that plasminogen activator inhibitor-1 (PAI-1) was upregulated fourfold in aggressive fibromatosis. We investigated the ability of bcatenin to regulate a PAI-1 reporter, and found that PAI-1 is an indirect target. To determine the role of PAI-1 in vivo, a mouse containing a targeted deletion in Pai-1 was crossed with a mouse that develops aggressive fibromatosis and gastrointestinal tumors (Apc/Apc1638N mouse). Pai-1 deficiency reduced the number of aggressive fibromatosis tumors formed, but not the number of gastrointestinal tumors. Deficiency of Pai-1 reduced tumor cell proliferation and motility rate. Although PAI-1 can alter cell motility by competing for a common binding site on vitronectin, blocking this site did not alter the motility rate. The number of cells moving through matrigel (invasion rate) did not change with Pai-1 deficiency, but because of the low motility rate the invasion index (invasion rate/motility) was increased in Pai-1-deficient cells. This suggests a proteolytic effect for PAI-1 regulating cell invasiveness. Our study found that, although PAI-1 has cellular effects that could inhibit or enhance tumor growth, on balance, it acts as a tumor enhancer in aggressive fibromatosis.
Introduction
Aggressive fibromatosis, also called desmoid tumor, is a benign soft tissue tumor, whose local behavior is similar to malignant processes (Dormans et al., 2001) . It is composed of a clonal proliferation of mesenchymal, fibroblast-like, cells (Alman et al., 1997b) , and can occur either as a sporadic lesion, or as a part of familial adenomatous polyposis or familial infiltrative fibromatosis, both conditions associated with a germ-line mutation in the adenomatous polyposis coli (APC) gene (Kinzler et al., 1991; Scott et al., 1996) . Most cases of sporadic aggressive fibromatosis harbor somatic mutations in either b-catenin or APC, resulting in b-catenin protein stabilization (Alman et al., 1997a; Tejpar et al., 1999) . b-Catenin is a critical signaling molecule involved in developmental processes, epithelial cell biology, and neoplasia. A multiprotein complex containing APC helps to regulate the protein level of b-catenin. Wingless (Wnt) signaling activation, mutations in b-catenin, or mutations in members of this multiprotein complex result in the b-catenin protein stabilization. Stabilized b-catenin can bind to members of the T-cell factorlymphoid enhancer factor (tcf-lef) family, forming a transcriptional activating complex (Miller et al., 1999; Roose and Clevers, 1999) .
b-Catenin protein stabilization was found to be sufficient to cause aggressive fibromatosis, as demonstrated using a transgenic mouse model (Cheon et al., 2002) . However, aggressive fibromatosis tumors occur at a greater frequency in a mouse harboring an Apc mutation, which behaves similar to familial infiltrative fibromatosis. The Apc/Apc1638N mouse carries a targeted mutant allele of the endogenous Apc gene corresponding to codon 1638. It develops large numbers of aggressive fibromatosis tumors, and has been utilized to investigate the implications of genes differentially regulated in aggressive fibromatosis in vivo (Fodde et al., 1994; Smits et al., 1998; van der Houven van Oordt et al., 1999; Poon et al., 2001; Tolg et al., 2003; Kong et al., 2004) .
Plasminogen activator inhibitor-1 (PAI-1) belongs to the family of serine protease inhibitors. It is implicated in processes such as tissue remodeling, thrombolysis, tumor invasion, and metastasis. Clinical investigations show a strong and independent prognostic value of PAI-1 in primary breast cancer (Grondahl-Hansen et al., 1993 Kute et al., 1998; Look et al., 2002) . PAI-1 inhibits plasminogen activation by tissue-type and urokinase-type plasminogen activator, regulating the activation of plasmin, which is capable of degrading a wide variety of extracellular proteins. In addition to its ability to bind and to inactivate plasminogen activators, there are other ligands that bind and may modulate the functions of PAI-1, including glucosaminoglycans, matrix proteins such as vitronectin, and members of the low-density lipoprotein receptor (LDLR) family. Although a high level of PAI-1 in tumor cells correlates with a more aggressive behavior in a number of tumor types Steinmetzer, 2003) , by decreasing the proteolytic activity in the extracellular matrix, PAI-1 prevents degradation of the matrix scaffold to which tumor cells need to adhere and through which they need to migrate (Schmitt et al., 1997) . This seemingly contradictory evidence suggests that perhaps PAI-1 modulates tumor cell behavior through an alternative cellular mechanism. The finding that PAI-1 does not alter the neoplastic phenotype in the polyomavirus middle T-antigeninduced breast cancer mouse model further confounds an understanding of the role of this protease inhibitor in neoplasia (Almholt et al., 2003) .
In this study, we show that PAI-1 is expressed at a high level in aggressive fibromatosis, and investigate the implications of PAI-1 in aggressive fibromatosis in vivo using the Apc/Apc1638N mouse.
Results

PAI-1 expression is elevated in aggressive fibromatosis
Using tissue from aggressive fibromatosis tumors and normal fascia from the same patients, we examined PAI-1 expression using semiquantitative RT-PCR. Six patient-matched tumor and normal fascial tissues were investigated. After normalizing to the control housekeeping gene GAPDH (reduced glyceraldehyde-phosphate dehydrogenase), PAI-1 expression was found to be significantly higher in the aggressive fibromatosis tumors than the normal fascial tissue from the same patient (relative densities 1.270.2 vs 0.370.1, Po0.05, Figure 1a ). Paraffin-embedded sections of human aggressive fibromatosis were used for immunochemical staining of PAI-1 protein. Most of the mesenchymal cells in the tumors and normal tissues showed some degree of PAI-1 staining, but there was a substantially increased intensity to the staining in aggressive fibromatosis tumor cells (Figure 1b ), compared to normal tissues located on the same slide ( Figure 1c ).
The PAI-1 promoter is not directly regulated by b-catenin Using NIH3T3 cells, we examined the ability of b-catenin stabilization to regulate activation of the PAI-1 promoter. A tetracycline-regulated b-catenin construct, as previously reported (Cheon et al., 2002) , which expresses b-catenin with its amino-terminus phosphorylation sites mutated, resulting in expression of a stabilized form of b-catenin in the tetracycline-free environment (Tet-off), was used. As a control, we examined the ability of the mutated b-catenin to activate the tcf reporter construct TOPFLASH, and TGF-b to regulate activation of the PAI-1 promoter construct P800-neo-luc (Abe et al., 1994) . There was no change in activation of the PAI-1 promoter (the luciferase activity of P800-neo-luc in NIH3T3) after activation of the stabilized b-catenin (608 000750 000 vs 552 000735 000 relative luminescence units, Figure 2a) . Expression of the stabilized b-catenin did result in a fourfold elevation in TOPFLASH reporter activity, compared to the control FOPFLASH reporter activity (data did not show), which is an increase in activity similar to that previously reported using mesenchymal cells (Meng et al., 2001) . Treating these cells with TGF-b resulted in an expected activation in the PAI-1 promoter activity (relative luminescence units 1 272 0007142 000, Figure 2a ). Thus, although PAI-1 levels are elevated in aggressive fibromatosis, it is not a direct target of b-catenin-mediated transcriptional activation, at least not within the area of the PAI-1 promoter we investigated.
To confirm the results of the reporter assays under more physiologic conditions, we used primary fibroblast cell cultures derived from a tetracycline-regulated b-catenin transgenic mouse, as reported previously (Cheon et al., 2002) . These cells express the same mutated, stabilized b-catenin as used in our reporter assays after the addition of doxycycline. Using RT-PCR, we found that Pai-1 expression was increased in the cell culture in which stabilized b-catenin is activated. However, this increase in Pai-1 expression could be blocked by the addition of TGF-b-neutralizing antibody (Figure 2b) , suggesting that the regulation of Pai-1 by bcatenin is TGF-b dependent.
PAI-1 deficiency reduces the number of aggressive fibromatosis tumors formed in Apc/Apc1638N male mice
We investigated the biological significance of PAI-1 in vivo using the Apc/Apc1638N mouse, which develops large numbers of aggressive fibromatosis tumors. Apc/ Apc1638N and Pai-1À/À mice (Carmeliet et al., 1993a, b; Smits et al., 1998) were mated to generate Apc/Apc1638N;Pai-1 þ / þ and Apc/Apc1638N;Pai-1À/À littermates. The number of aggressive fibromatosis tumors that formed in male Apc/Apc1638N;Pai-1À/À mice was significantly reduced compared to the number that developed in Apc/Apc1638N;Pai-1 þ / þ littermates at 6 months of age (12.772.3 vs 18.672.3, Po0.05, Figure 3 ). However, there was no significant difference in the aggressive fibromatosis tumor volume (173747 vs 230763 cm 3 , P>0.05, Figure 4 ) or in the number of gastrointestinal tumors formed (0.6770.44 vs 1.3370.70, P>0.05). In distinction to the male mice, which develop larger numbers of aggressive fibromatosis tumors, little difference in aggressive fibromatosis tumor number or size was seen in female mice (3.571.4 vs 4.371.7, P>0.05, Figure 3 ; 29736 vs 48731 cm 3 , P>0.05, Figure 4 ) or in the number of gastrointestinal tumors formed (1.170.4 vs 0.770.5, P>0.05).
PAI-1 deficiency reduces cell proliferation and motility, but increases invasion index in aggressive fibromatosis
To determine how PAI-1 deficiency alters cell behavior in aggressive fibromatosis, we studied primary cell Figure 5a and b). Although we found no significant difference in the invasiveness as determined using a matrigel invasion assay (4.671.8 vs 5.271.4, Figure 5c ), the invasion index, which was calculated by dividing the mean of the invasiveness by the mean of the motility, was higher in cells derived from tumors from Apc/Apc1638N; Pai-1À/À mice than Apc/Apc1638N;Pai-1 þ / þ (0.867 0.19 vs 0.3970.1, Po0.05, Figure 5d ).
PAI-1 does not alter aggressive fibromatosis cell motility by interfering with vitronectin interactions
One mechanism by which PAI-1 can regulate cell motility is by competing for a vitronectin-binding site with the urokinase-type plasminogen activator receptor (PLAUR). The interactions between the PLAUR and vitronectin inhibit cell motility, and as such increased levels of PAI-1 inhibit this interaction and increase cell motility (Waltz et al., 1997) . RT-PCR showed that murine aggressive fibromatosis cells express Plaur (Figure 6a ), raising the possibility that this mechanism is active in these tumors. Cell cultures derived from tumors from either Apc/Apc1638N;Pai-1 þ / þ or Apc/ Apc1638N;Pai-1À/À mice were treated with 500 mM of a synthetic peptide that competes for the common interaction site between vitronectin, PAI-1, and PLAUR (VN-4, Waltz et al., 1997) , or a randomly scrambled sequence of this peptide (SC-4). Cell motility in aggressive fibromatosis cell cultures derived from either Apc/Apc1638N;Pai-1 þ / þ or Apc/Apc1638N;Pai-1À/À were not changed by the addition of VN-4 (342737.6 for VN-4 and 344744.8 for SC-4 in Apc/Apc1638N;Pai-1 þ / þ , P>0.05; 109731.2 for VN-4 and 18575.6 for SC-4 in Apc/Apc1638N;Pai-1À/À, P>0.05, Figure 6b ). This suggests that the effect of PAI-1 promoting cell motility is independent of the interaction between the PLAUR and vitronectin in murine aggressive fibromatosis.
Surprisingly, we found a change in cell proliferation in aggressive fibromatosis cell culture derived from Apc/ Apc1638N;Pai-1À/À mice with the addition of VN-4 (7.6%70.01 for VN-4 and 12.2%70.02 for SC-4, Po0.05, Figure 6c ), with this resulting in a decrease in cell proliferation compared to cells treated with the control scrambled peptide (SC-4). In contrast, cells derived from Pai-1 þ / þ animals did not show changes in cell proliferation with VN-4 treatment compared to SC-4. This suggests that an interaction with vitronectin has a potential to regulate cell proliferation, perhaps by altering the activity of PLAUR or its ability to bind other factors. However, this could also be a nonspecific effect, and these data do not explain the mechanism by which PAI-1 increases cell proliferation in aggressive fibromatosis.
Discussion
Here, we show that PAI-1 gene expression and its protein product are elevated in aggressive fibromatosis, and we show in vivo that PAI-1 plays an important role in the development of this tumor type. Pai-1 deficiency reduced cell proliferation and motility in cells derived from murine aggressive fibromatosis tumors. Although motility was decreased, overall invasiveness did not differ between Pai-1À/À and Pai-1 þ / þ tumors, resulting in an increase in invasion index (invasion/ motility). Although Pai-1 deficiency results in the development of a smaller number of aggressive fibromatosis tumors, the tumors that form in Pai-1À/À mice did not differ in size from tumors formed in Pai-1 þ / þ mice. In concert with our previous data showing that matrix metalloproteinase activity regulates cell invasiveness and also aggressive fibromatosis tumor size (Kong Female Apc/Apc1638N mice develop fewer and smaller aggressive fibromatosis tumors compared to male littermates. The reason for this is not fully elucidated. However, it may be due to the interaction between androgen and b-catenin, as androgen stimulation alters the nuclear translocation of b-catenin and influences its subcellular distribution by shuttling b-catenin to the nucleus, as demonstrated in neuronal cells and prostate cancer cells (Mulholland et al., 2002; Pawlowski et al., 2002) . The lack of significant differences in tumor numbers in female mice, as opposed to male mice with Pai-1 deficiency, may be related to the substantially smaller number of tumors that form, which decreases the statistical power to detect differences.
Although Pai-1 deficiency reduces the number of aggressive fibromatosis formed, it did not alter the number of gastrointestinal tumors formed. Since aggressive fibromatosis is originated from mesenchymal cells, while gastrointestinal tumors are originated from epithelial cells, this raises the possibility that PAI-1 regulates cell behavior differently in cells of mesenchymal origin than in cells of epithelial origin. Previous studies report on different effects of PAI-1 in different cell types. PAI-1 inhibits cell motility in epithelialoriginated tumors, such as human amnion WISH cells, epidermoid carcinoma HEp-2 cells, and glioma cells Hjortland et al., 2003) . In contrast, PAI-1 promotes SK-N-BE(2) human neuoblastoma cell detachment from vitronectin and human preadipocyte migration (Sugiura et al., 1999; Crandall et al., 2000) . PAI-1 inhibits proliferation of hepatocellular carcinoma (Morita et al., 1999) , but enhances proliferation in fibrosarcoma cells (Gutierrez et al., 2000) . PAI-1, as an inhibitor of extracellular matrix degradation, decreases invasion in both epithelial-and mesenchymal-originated tumors, such as colon carcinoma cells, hepatocellular carcinoma, and fibrosarcoma cells (Cajot et al., 1990; Morita et al., 1999) . Thus, PAI-1 has different cellular effects in different cell types, especially in regulating cell motility and proliferation, while it seems to play a common role in multiple cell types, including in aggressive fibromatosis, as a positive regulator of cell invasion. There are a variety of ways in which PAI-1 can regulate cell motility and invasiveness. Overexpression of PAI-1 can inhibit cell motility and invasion through extracellular matrix components, like laminin and collagen, by directly regulating proteolytic activity which can degrade some matrix components (Hjortland et al., 2003) . PAI-1 can also regulate cell motility by competing for binding to vitronectin and PLAUR . By disrupting PLAUR binding to vitronectin, cell adhesion to the extracellular matrix is decreased. In this way, PAI-1 can promote cellular motility by regulating the interaction between the PLAUR and vitronectin, which is independent of its proteolytic activity (Waltz et al., 1997) . Our data showing no change in motility using the synthetic peptide VN-4, which competes for binding between PLAUR and vitronectin, suggest that this mechanism is not responsible for dysregulating cell motility in aggressive fibromatosis.
Although the number of cells moving through matrigel was not altered by PAI-1 level in aggressive fibromatosis, the invasion index increased, as the motility rate differed significantly between Pai-1 þ / þ and Pai-1À/À tumor cells. The increased invasion index in Pai-1-deficient tumor cells is likely caused by a proteolytic mechanism, perhaps through regulation of plasminogen and plasmin, which will degrade extracellular matrix components such as those present in matrigel. PAI-1 may also act independently of plasmin to degrade the extracellular matrix. A role for PAI-1 as a regulator of extracellular matrix degradation has been demonstrated in a variety of cell types, such as in colon carcinoma and fibrosarcoma cells (Cajot et al., 1990) .
A role for PAI-1 as a positive regulator of cell proliferation is suggested in another tumor of mesenchymal cell origin, fibrosarcoma, in which PAI-1 deficiency decreased proliferation (Gutierrez et al., 2000) . Although the mechanism by which PAI-1 regulates cell proliferation is unclear, it can play a role through the regulation of cell surface proteins. PAI-1 can form a complex with urinary plasminogen activator (PLAU) bound to PLAUR. This inhibitor-proteinase-receptor complex is removed from the cell surface via members of the LDLR family. The plasminogen activatorinhibitor complex then undergoes lysosomal degradation, and PLAUR is recirculated and reappears on the cell surface (Nykjaer et al., 1997) . PAI-1 also plays a similar role in the clearance of tissue plasminogen activator (PLAT). The process of removal of plasminogen activators by first forming complexes with PAI-1 and then binding to LRP not only serves as a clearance mechanism for proteolytic activity, but also to redistribute PLAUR to the leading edge of migrating and invading cells, resulting in cell motility. However, endocytosis of these complexes may activate signaling events that mediate the effects of PAI-1 on various cell functions (Binder et al., 2002) . It is possible that such a pathway could alter cell signaling in mesenchymal cells, ultimately regulating cell proliferation. PAI-1 has been implicated in the regulation of apoptosis (Kwaan et al., 2000) . Although the apoptosis rate in aggressive fibromatosis is quite low , it is still possible that the observed differences between the two genotypes with regard to tumor formation and cell proliferation could be explained by a subtle difference in apoptosis rate. PAI-1 is also reported to play a role in tumor angiogenesis (Bajou et al., 1998; Rakic et al., 2003) . Since aggressive fibromatosis tumors exhibit relatively low vascularity , alterations in angiogenesis are unlikely to be responsible for the differences in numbers of aggressive fibromatosis tumors that developed in the mice.
In order to investigate how b-catenin regulates the PAI-1 expression in aggressive fibromatosis, we used a murine fibroblast cell culture derived from a tetracycline-regulated b-catenin transgenic mouse (Cheon et al., 2002) , which expresses b-catenin with its amino-terminus phosphorylation sites mutated, resulting in expression of a stabilized form of b-catenin that is transcriptionally active after induction by tetracycline. Our data showed that, although Pai-1 expression is increased when b-catenin protein is stabilized, this does not result in activation of a PAI-1 reporter construct, P800-neo-luc (Abe et al., 1994) . Thus, PAI-1 is not a direct target of b-catenin-mediated transcriptional activation, at least not within the area of the PAI-1 promoter we investigated. However, PAI-1 is expressed in a cell-cycle-dependent manner. Its expression is induced soon after exposure of growth-arrested cells to serum-containing medium, and downregulated prior to DNA synthesis in the G1-to-S-phase transition, and this pattern of expression appears again in the subsequent cell cycle (Grimaldi et al., 1986; Ryan et al., 1996; Zavizion et al., 1998) , and the 5 0 flanking region of human PAI-1 gene contains binding sites for many transcription factors involved in cell cycle regulation (Descheemaeker et al., 1992 , Kutz et al., 1995 Dennler et al., 1998) . Thus, it is possible that the elevated levels of PAI-1 in aggressive fibromatosis could be due to a larger proportion of cells being in a mitotic state. Indeed, b-catenin protein stabilzition does cause an increased proliferation rate in fibroblasts (Cheon et al., 2002) .
Previously, we investigated several other genes that are upregulated in aggressive fibromatosis, using the Apc/Apc1638N mouse Tolg et al., 2003; Kong et al., 2004) . MMPs regulated aggressive fibromatosis tumor size, but not number. RHAMM deficiency significantly decreased the number and size of aggressive fibromatosis tumors formed. PAI-1 altered the aggressive fibromatosis tumor number, but not size. This difference raises the possibility that the effects of differentially regulated genes might act synergistically. A strategy to block several targets has the potential to be developed into a pharmacological approach to this tumor type. Our data suggest PAI-1 as a potential therapeutic target for aggressive fibromatosis, a lesion in which effective treatment is lacking.
Materials and methods
Materials
Six pairs of sporadic aggressive fibromatosis and normal fascia samples from same patients were collected, while the patients were under surgical excision of the tumor. All tumors contained a mutation resulting in b-catenin protein stabilization, as reported previously (Tejpar et al., 2001) . The samples were cryopreserved as soon as possible after resection and stored in liquid nitrogen vapor for later RNA extraction. The human and animal experiments had been approved by the ethical review board of The Hospital for Sick Children.
PAI-1 expression studies
PAI-1 expression level in human aggressive fibromatosis and normal tissues was measured by semiquantitative RT-PCR and Southern blot. Total RNA was extracted using Trizol reagents (Invitrogen) and reverse transcripted into cDNA with a poly-T primer. PCR primer pairs for human reduced glyceraldehyde-phosphate dehydrogenase (GAPDH) and human PAI-1 were chosen to amplify a region of cDNA crossing an intron. For GAPDH, 5 0 -CCA TGG AGA AGG CTG GGG was used as sense primer and 5 0 -CAA AGT TGT CAT GGA TGA CC as antisense primer, which produced a 195 bp PCR product. For PAI-1, 5 0 -GAA CTT CAG GAT GCA GAT G was used as sense primer and 5 0 -CTG ATC ATA CCT TTT GTG TG as antisense primer, which produced a 525 bp PCR product. Their amplification profile involved denaturation at 941C for 20 s, primer annealing at 551C for 30 s, and extension at 721C for 30 s on a Perkin-Elmer/Cetus thermal cycler 9600. The optimal amplification cycles were selected within the exponential phase for each target gene, 30 cycles for GAPDH, and 33 cycles for PAI-1. The PCR products of tumor and normal tissue for PAI-1 and GAPDH expression under the optimal amplification cycles were electrophoresed and transferred to the positive nylon membrane. Probes for PAI-1 and GAPDH were labeled with digoxigenin using the DIG Easy Hyb kit (Boehringer Mannheim). Hybridization was carried out overnight at 501C and detected with an anti-digoxigenin antibody and chemiluminescence (Boehringer Mannheim). The intensity of the bands was scanned to measure the level of expression. The expression of GAPDH was used as control. The expression level of the target gene PAI-1 was represented as the ratio of its intensity vs the intensity of the control gene, under the condition that the same amount of the cDNA template was used for the target gene and the control gene.
Pai-1 expression in murine cells was conducted using fibroblast cells derived from a tetracycline-regulated b-catenin transgenic mouse as reported previously (Cheon et al., 2002) , which expresses b-catenin with its amino-terminus phosphorylation sites mutated, resulting in expression of a stabilized form of b-catenin after addition of doxycycline (Tet-on), was established and maintained with DMEM, 10% Tet system approved Tet-free fetal bovine serum (Clontech), 2 mM L-glutamine, 100 U/ml penicillin G sodium, and 100 mg/ml streptomycin sulfate. Cells were treated with distilled water alone, 2 ng/ml of doxycycline alone, 100 mg/ml of pan-specific TGF-b neutralizing antibody (AB-100-NA, R&D systems) alone, or both 2 ng/ml of doxycycline and 100 mg/ml of panspecific TGF-b-neutralizing antibody. After 12 h of treatment, total RNA and protein were extracted from all of the plates. The stabilization of b-catenin protein after addition of doxycycline was verified by Western blot according to the method that had been published before (Cheon et al., 2002) . Pai-1 expressions from the different treatment groups were PAI-1 in aggressive fibromatosis C Fen Li et al evaluated by semiquantitative RT-PCR. Total RNA was extracted and reverse transcripted into cDNA by the method used for human samples. PCR primer pairs for mouse reduced glyceraldehyde-phosphate dehydrogenase (Gapdh) and mouse Pai-1 were chosen to amplify a region of cDNA crossing an intron. For Gapdh, 5 0 -TGG CAT TGC TCT CAA TGA C was used as sense primer and 5 0 -TGT GAG GGA GTA GCT CAG as antisense primer, which produced a 199 bp PCR product. For Pai-1, 5 0 -GCT GTA GAC GAG CTG ACA C was used as sense primer and 5 0 -TTT TGC AGT GCC TGT GCT A as antisense primer, which produced a 502 bp PCR product. Their amplification profile involved denaturation at 941C for 30 s, primer annealing at 561C for 30 s, and extension at 721C for 60 s on a Perkin-Elmer/Cetus thermal cycler 9600. The optimal amplification cycles were selected within the exponential phase for each target gene, 28 cycles for both Gapdh and Pai-1. The PCR products under the optimal amplification cycles were electrophoresed and the gel images were saved in the computer.
Expression of Plaur in murine aggressive fibromatosis cells
The expression of Plaur in aggressive fibromatosis cells derived from Apc/Apc1638N; Pai-1 þ / þ and Apc/Apc1638N; Pai-1À/À mice was investigated by RT-PCR. Total RNA was extracted and reverse transcripted into cDNA by the method used for human samples. PCR primer pairs for the murine urokinasetype plasminogen activator receptor (Plaur) were chosen to amplify a region of cDNA crossing an intron. 5 0 -CAC AGC AGG TTT CCA TAG was used as sense primer and 5 0 -AGG AGA CAG AGA CGT TGA G as antisense primer, which produced a 336 bp PCR product. The amplification profile involved denaturation at 941C for 30 s, primer annealing at 561C for 30 s, and extension at 721C for 60 s on a PerkinElmer/Cetus thermal cycler 9600. The amplification cycle was 40 cycles. The PCR products under the optimal amplification cycles were electrophoresed and the gel images were saved in the computer.
Immunochemical staining of PAI-1 protein
Paraffin-embedded sections were measured for expression of PAI-1 protein in human aggressive fibromatosis and compared to the surrounding normal tissue on the same slide using the procedure modified from Yang et al. (2000) . The paraffin sections were de-waxed by immersed in xylene, then rehydrated by incubating in a decreasing ethanol series and washed in water. The endogenous peroxidase activity was quenched by incubating with 3% hydrogen peroxide in water for 3 min at room temperature. After washing with PBS at pH 7.4, the samples were incubated in 1% BSA (Sigma, St Louis, MO, USA) in PBS, at pH 7.4, for 20 min to block nonspecific protein binding. Tissue sections were then incubated at 41C overnight in a humidity chamber with 5 mg/ml of goat antihuman PAI-1 (395G, IgG fraction purified by affinity chromatography on Protein A-sepharose, American Diagnostica Inc, Greenwich, CT, USA) in PBS with 1% BSA, or nonimmune goat IgG (19140, Sigma) in PBS with 1% BSA as negative control. After three washes with PBS, the sections were incubated with 7.5 mg/ml of biotinylated anti-goat IgG in PBS with 1% BSA at room temperature for 40 min. After washing with PBS, a streptavidin-biotin-peroxidase (ABC-HRP) reagent (PK-7100, Vector Laboratories Inc, Burlingame, CA, USA), pre-diluted 1 : 200 in PBS, was applied to all sections and incubated for 30 min at room temperature. 3,3 0 -Diaminobenzidine tetrahydrochloride (DAB, 0.05%) mixed with 0.01% hydrogen peroxide in PBS from peroxidase substrate solution (SK-4100, Vector Laboratories Inc.) was used as a substrate, which forms a brown end product at the site of the target antigen after 2 min of incubation. After washing in water, all sections were counterstained with Harris hematoxylin. Then, the sections were dehydrated and permanently mounted in nonaqueous mounting media VectaMount (H-5000, Vector Laboratories Inc.). The stained sections were viewed and evaluated by light microscopy.
PAI-1 promoter studies
Gene transfection was performed in NIH3T3 cell which was stably infected with pRev-tTA-IN (MEF Tet-Offt Cell Line) (Clontech) and maintained with DMEM, 10% Tet system approved Tet-free fetal bovine serum (Clontech), 2 mM L-glutamine, 100 U/ml penicillin G sodium, and 100 mg/ml streptomycin sulfate. Cells were seeded in a six-well tissue culture plate and incubated at 371C in a CO 2 incubator until the cells reached 50-80% confluent. LipofectAminet reagent (Gibco Life Technologies, Inc.) was used for gene transfection at a 1 : 10 vector DNA to liposome ratio. A 5-h incubation of the cells with the DNA-liposome complexes was utilized. Cells were harvested 24 h after the start of transfection with Reporter Lysis Buffer (Promega), which allows luciferase and b-galactosidase reporter enzyme assays to be performed from extracts of cells co-transfected with vectors carrying these genes. To regulate b-catenin, we used a tetracycline-regulated construct (pd2EGFP-pBI-mutated b-catenin) as reported previously (Cheon et al., 2002) , which expresses b-catenin with amino-terminus phosphorylation sites mutated, resulting in expression of a stabilized and transcriptionally active form of b-catenin in the tetracycline-free environment (Tet-off). To measure b-catenin transcriptional activity, we used the tcf reporter construct (TOPFLASH) Morin et al., 1997) . The PAI-1 promoter construct P800-neo-luc (Abe et al., 1994) was utilized as reporter construct to measure PAI-1 transcriptional activation. Rouse Sarcoma Virus beta-galactosidase DNA (pCMV-b) was used as a control for transfection efficiency. Cells were incubated with either 4 ng/ml TGF-b (R and D systems, Minneapolis) or carrier (1 mg/ml bovine serum albumin as a control for PAI-1 promoter activation) after transfection with PAI-1 promoter luciferase reporter (0.4 mg p800-neo-luc), a b-galactosidase expression vector (0.2 mg pCMV-b), and either 0.9 mg of empty vector (pd2EGFP-pBI) or 0.9 mg of a stable b-catenin (pd2EGFP-pBI-mutated bcatenin). Relative luminescence was detected using a luminometer, and standardized to b-galactosidase activity. Experiments were performed nine times, and the Student's t-test was used to compare between groups.
Generation of Apc/Apc1638N;PAI-1À/À and Apc/ Apc1638N;PAI-1 þ / þ mice Either the Pai-1 mice (Carmeliet et al., 1993a, b) or the Apc/ Apc1638N mice (Smits et al., 1998) were backcrossed for at least five passages by sib breeding on a C57black background. Genotyping of both Pai-1 'knockout' mice and Apc/Apc1638N mice was carried out using PCR methods. The three primers for Pai-1 genotyping were mPAI 1.1p (5 0 -TTC ATG CCC TCT GGT CGC TG), mPAI 1.2m (5 0 -CTC CCT CCC TCC CAG TGA CTT G), and mPGK 2m (5 0 -GCC TTG GGA AAA GCG CCT C), and the amplification profile involved denaturation at 941C for 1 min, primer annealing at 601C for 1 min, and extension at 721C for 1 min on a Perkin-Elmer/ Cetus thermal cycler 9600 for 35 cycles, which produced a 350 bp PCR product for wild-type allele and 200 bp PCR product for mutant allele. The three primers for Apc/ PAI-1 in aggressive fibromatosis C Fen Li et al Apc1638N genotyping were APC-A2 (5 0 -TCA GCC ATG CCA ACA AAG TCA), APC-C2 (5 0 -GGA AAA GTT TAT AGG TGT CCC TTC T) and PN3 (5 0 -GCC AGC TCA TTC CTC CAC TC), and the amplification profile involved denaturation at 951C for 30 s, primer annealing at 541C for 30 s, and extension at 721C for 30 s on a Perkin-Elmer/Cetus thermal cycler 9600 for 35 cycles, which produced a 250 bp PCR product for wild-type allele and 400 bp PCR product for mutant allele.
Pai-1 þ /À and Apc/Apc1638N mice were mated to generate F1 Apc/Apc1638N;Pai-1 þ /À mice. The F1 mice were used to generate 10 male and 10 female F2 Apc/Apc1638N;Pai-1 þ / þ and 10 male and 10 female F2 Apc/Apc1638N;Pai-1À/À mice by sibling breeding. The F2 mice were killed at the age of 6 months. The number and size of tumors were blindly scored as reported previously (Smits et al., 1998) . Aggressive fibromatosis tumors, cutaneous cysts, and gastrointestinal tract tumors were recorded.
Primary cell cultures of mouse tumor and in vitro assays
The mouse aggressive fibromatosis tumors were excised under sterile condition and cells were mechanically dissociated and cultured with DMEM, 10% fetal bovine serum, and 2 mM L-glutamine at 371C in a CO 2 incubator as described previously . For proliferation studies, cells were seeded at 2.5 Â 10 4 cells/ml on glass coverslips in a six-well plate and cultured in DMEM with 10% fetal bovine serum at 371C. After the cells had been cultured for 24 h, the S-phase cells were labeled overnight by supplementation of the cell culture medium with BrdU (Sigma, St Louis, MO, USA; 10 mM) and detected by mouse monoclonal anti-BrdU (DAKO, Demark; 1 : 100) containing DNase-1 (Sigma; 50 mg/ ml) by the published method (Tischler et al., 1992) . After the final step, the glass coverslips were removed from the well and mounted on microscope slides by mounting the medium with DAPI to stain the nuclei. The number of S-phase cells and total number of nuclei were photographed and counted in each of five fields at the center and four corners on the squire glass coverslip at Â 100 magnification using light and UV fluorescence microscopy. Cell motility and invasion assays were performed. Cells were seeded at 5 Â 10 4 cells/ml and cultured with DMEM and 10% fetal bovine serum for 22 h at 371C in the BioBoat s culture inserts (BD Bioscience) for motility assay and BioBoat s Matrigel invasion chambers (BD Bioscience) for invasion assay. After the incubation period, cells on the upper surface of the membrane were removed, but cells that migrated to the lower surface of the membrane were fixed to the membrane with 4% paraformaldehyde. The membranes were then excised from the insert and mounted on microscope slides by mounting the medium with DAPI to stain the nuclei. The total number of nuclei was counted in each of five fields across the diameter of the member at Â 400 magnification using UV fluorescence microscopy. The above cell proliferation, motility, and invasion assays were conducted with three replicates and repeated three times.
Urokinase receptor and vitronectin interaction studies
VN-4 (RGHSRGRNQNSR), a synthetic peptide corresponding to vitronectin residues 364-375, and SC-4 (NRQRGSNRSRGH), a randomly scrambled sequence of peptide VN-4, were synthesized according to Waltz et al. (1997) . Primary ecll cultures from murine aggressive fibromatosis cells derived either from Apc/Apc1638N;Pai-1 þ / þ or Apc/Apc1638N;Pai-1À/À mice were treated with either 500 mM VN-4 or SC-4. For proliferation studies, the cells were labeled for 20 h by addition of BrdU, added at the same time as the peptide. For cell motility and invasion assays, the total number of nuclei was counted in all fields across one diameter of the membrane at Â 400 magnification using UV fluorescence microscopy.
Statistical analysis
The counting process was conducted by a blinded observer. Means and 95% confidence intervals were calculated. The t-test was applied to compare differences.
